此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

L-Citrulline Versus Tamsulosin for Medical Expulsive Therapy of Distal Ureteral Stones

2026年5月25日 更新者:Hany Fathy Badawy, MD、Beni-Suef University

L-Citrulline Versus Tamsulosin for Medical Expulsive Therapy of Distal Ureteral Stones: A Prospective Randomized Study

This study will compare L-citrulline and tamsulosin as medical expulsive therapy for adults with single distal ureteral stones.

Eligible participants with a single distal ureteral stone measuring 5 to 10 mm will be randomly assigned to receive either oral L-citrulline 750 mg twice daily or oral tamsulosin 0.4 mg once daily. Treatment will continue until documented stone passage or completion of 4 weeks of therapy, whichever occurs first.

Participants will be followed weekly for up to 4 weeks. The main outcome is stone expulsion within 4 weeks. The study will also assess time to stone expulsion, pain episodes, analgesic use, need for additional intervention, and adverse events.

研究概览

详细说明

This is a prospective, randomized, controlled trial conducted at the outpatient Urology Clinic, Beni-Suef University Hospital.

The study will include adult patients aged 18 to 60 years with a single distal ureteral stone measuring 5 to 10 mm, normal renal function, and controlled pain. Patients with fever or active urinary tract infection, severe hydronephrosis, solitary kidney, pregnancy, previous ureteric surgery, multiple stones, or an indication for urgent surgical intervention will be excluded.

Eligible participants will be randomized in a 1:1 ratio to one of two treatment groups. The L-citrulline group will receive oral L-citrulline 750 mg twice daily. The tamsulosin group will receive oral tamsulosin 0.4 mg once daily. Treatment will be discontinued upon stone passage or after completion of 4 weeks of therapy, whichever occurs first. Both groups will receive standard supportive care, including analgesics as needed, hydration advice, and use of a stone strainer.

Participants will be evaluated weekly for 4 weeks. Follow-up assessments will include symptom review, pain assessment using the Visual Analog Scale, documentation of pain episodes, analgesic requirements, adverse event monitoring, and imaging assessment using ultrasound with or without KUB, with low-dose computed tomography when clinically needed.

The primary outcome is stone expulsion rate within 4 weeks. Stone expulsion will be confirmed by patient-reported stone passage with stone capture, or by absence of the stone on follow-up imaging. Secondary outcomes include time to stone expulsion, number of pain episodes, analgesic use, need for additional intervention such as ureteroscopy or ureteral stenting, and adverse events.

研究类型

介入性

注册 (估计的)

120

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Beni Suweif Governorate
      • Banī Suwayf、Beni Suweif Governorate、埃及、02456
        • 招聘中
        • Department of Urology- Beni-Suef University Hospitals
        • 接触:
        • 首席研究员:
          • Hany F Badawy, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  • Adults aged 18 to 60 years.
  • Single distal ureteral stone.
  • Stone size 5 to 10 mm.
  • Normal renal function.
  • Controlled pain.
  • Willingness to comply with follow-up for 4 weeks.
  • Written informed consent.

Exclusion Criteria:

  • Fever or active urinary tract infection.
  • Severe hydronephrosis.
  • Solitary kidney.
  • Pregnancy.
  • Previous ureteric surgery.
  • Multiple ureteral stones.
  • Indication for urgent surgical intervention.
  • Known hypersensitivity or contraindication to L-citrulline or tamsulosin.
  • Inability to complete follow-up.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:L-Citrulline Plus Tamsulosin Placebo
Participants will receive oral L-citrulline 750 mg twice daily plus a matched tamsulosin placebo once daily. Treatment will continue until documented stone passage or completion of 4 weeks of therapy, whichever occurs first. Standard supportive care will be provided as needed.
Oral L-citrulline 750 mg twice daily will be administered until documented stone passage or completion of 4 weeks of therapy, whichever occurs first.
有源比较器:Tamsulosin Plus L-Citrulline Placebo
Participants will receive oral tamsulosin 0.4 mg once daily plus a matched L-citrulline placebo twice daily. Treatment will continue until documented stone passage or completion of 4 weeks of therapy, whichever occurs first. Standard supportive care will be provided as needed.
Oral tamsulosin 0.4 mg once daily will be administered until documented stone passage or completion of 4 weeks of therapy, whichever occurs first.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Stone Expulsion Rate Within 4 Weeks
大体时间:Within 4 weeks after randomization
Stone expulsion rate will be defined as the proportion of randomized participants with confirmed stone passage within 4 weeks. Stone expulsion will be confirmed by patient-reported stone passage with stone capture, or by absence of the ureteral stone on follow-up imaging.
Within 4 weeks after randomization

次要结果测量

结果测量
措施说明
大体时间
Time to Stone Expulsion
大体时间:From randomization up to 4 weeks
Time to stone expulsion will be defined as the number of days from randomization to confirmed stone passage. Stone passage will be confirmed by patient-reported stone passage with stone capture, or by absence of the ureteral stone on follow-up imaging.
From randomization up to 4 weeks
Number of Pain Episodes
大体时间:From randomization up to 4 weeks
The number of renal colic pain episodes reported by each participant during the follow-up period will be recorded and compared between the study groups.
From randomization up to 4 weeks
Analgesic Use
大体时间:From randomization up to 4 weeks
Analgesic use will be assessed by recording the number of analgesic doses required by each participant during the follow-up period.
From randomization up to 4 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Hany F Badawy, MD、Faculty of Medicine, Beni-Suef University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月6日

初级完成 (估计的)

2026年10月1日

研究完成 (估计的)

2026年11月1日

研究注册日期

首次提交

2026年5月25日

首先提交符合 QC 标准的

2026年5月25日

首次发布 (实际的)

2026年6月1日

研究记录更新

最后更新发布 (实际的)

2026年6月1日

上次提交的符合 QC 标准的更新

2026年5月25日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared because the study is an investigator-initiated single-center clinical trial and the informed consent does not include a specific plan for external individual-level data sharing. Only aggregated, de-identified study results will be reported. Any future sharing of de-identified individual participant data would require additional approval from the Research Ethics Committee.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅